Session 5
A sunny day may change your risk assessment – What toxicologists should know about photosafety
Programme of the Session
- S05-01
Clinical photobiology: What happens when sun meets the skin?
Sally Ibbotson
Department of Dermatology, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom - S05-02
How much is too much: Monitoring our daily sunlight exposure
Peter Knuschke
Department of Dermatology, Medical Faculty, Technische Universitaet Dresden, Dresden, Germany - S05-03
Photo-safety assessment for cosmetics based on in vitro tests
Uwe Pfannenbecker, Horst Wenck, Andreas Schepky
Front End Innovation, Beiersdorf AG, Hamburg, Germany - S05-04
Photosafety evaluation for drugs, a step-wise strategy from photons to patients
Daniel Bauer
Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland - S05-05
In vitro phototoxicity testing and human health risk assessments for agrochemicals
Manoj Aggarwal, Marco Corvaro, Alistair Morriss, Jyotigna Mehta
Human Health Assessment, Dow AgroSciences, Abingdon, Oxfordshire, United Kingdom
Session Abstract
Sunlight alone – precisely its ultraviolet fraction – acts already as a complete human carcinogen (IARC “group 1”). Its deleterious acute effects (sun burn) belong almost to our general education. Still, it can be worse: by intentional use of cosmetics or pharmaceuticals or by unintentional exposure to chemicals. In this way we may enhance significantly our risk to develop adverse, light induced skin reactions including skin tumours. Therefore, it is fundamental to understand as a toxicologist the role of sunlight per se. More important, however, might be to also understand how to help minimize sunlight-induced adverse reaction caused by exogenous agents. The presentations of this workshop will address therefore both the role of sunlight in the context of human behaviour and the impact of exogenous photosensitizers being used in cosmetic, pharmaceutical or agrochemical products.
